EC Approves Amivantamab Plus Lazertinib for First-Line EGFR-Mutated NSCLC
• The European Commission has approved amivantamab plus lazertinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC). • The approval is based on the Phase 3 MARIPOSA trial, which showed superior progression-free survival compared to osimertinib. • The combination therapy reduced the risk of disease progression or death by 30% compared to osimertinib monotherapy. • Common adverse events were manageable and primarily Grade 1 or 2, supporting the combination's safety profile.
CHMP Recommends Subcutaneous Amivantamab for EGFR-Mutated NSCLC Treatment
The CHMP has recommended subcutaneous amivantamab with lazertinib for first-line treatment of NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
RYBREVANT Plus Chemotherapy Shows Positive Survival Trend in EGFR-Mutated Lung Cancer
Updated results from the Phase 3 MARIPOSA-2 study show RYBREVANT plus chemotherapy demonstrates a favorable trend toward improved overall survival.